Interferon Alfa News and Research

RSS
Immuno-oncology may accelerate the development of treatments for COVID-19

Immuno-oncology may accelerate the development of treatments for COVID-19

Clinical trial to evaluate two-drug immunotherapy combination in cancer patients with COVID-19

Clinical trial to evaluate two-drug immunotherapy combination in cancer patients with COVID-19

Updated USPSTF recommendations on hepatitis C screening

Updated USPSTF recommendations on hepatitis C screening

Roswell Park moving three-pronged immunotherapy strategy forward with support from DoD grant

Roswell Park moving three-pronged immunotherapy strategy forward with support from DoD grant

Chronic fatigue syndrome connected with an overactive immune system

Chronic fatigue syndrome connected with an overactive immune system

FDA grants approval for new biosimilar to treat multiple types of cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

Lancet study compares prices of new cancer drugs in high-income countries

Lancet study compares prices of new cancer drugs in high-income countries

Combining medications may increase HBsAg loss in HBV patients

Combining medications may increase HBsAg loss in HBV patients

Biomedical scientists explore mechanisms of novel treatments for HCV

Biomedical scientists explore mechanisms of novel treatments for HCV

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Sunitinib shows promise against metastatic renal cell carcinoma

Sunitinib shows promise against metastatic renal cell carcinoma

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

Biomarker predicts temsirolimus benefit in renal cancer

Biomarker predicts temsirolimus benefit in renal cancer